AUTHOR=Zhu Yan , Ding Zhechun , Wang Yini , Wu Qing , Chen Dongmei , Wang Luanhong , Li Yuancheng , Yao Yao , Huang Jiman , Li Yun , Wang Xiaojing , Lin Yanchun , Guan Tian , Zeng Haoyu , Li Congzhu 

TITLE=BME-free primary patient-specific organoids obtained with a one-day mimicking method to replicate the corresponding tumor for personalized treatment options

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1239957

DOI=10.3389/fonc.2023.1239957

ISSN=2234-943X

ABSTRACT=Organoid technology has advanced significantly in recent years. However, current cancer organoid methods involve creating 3D tumor tissue from 2D cancer cells or cell clusters, primarily for cancer research purposes aimed at investigating related molecular and cellular mechanisms of tumor development. These methods are researchdriven, not tailored towards clinical applications, and cannot provide personalized information for individual patients. Yet, in cancer treatment, every minute counts. Due to the unpredictable behavior of cancer cells caused by continuous mutations, each cancer patient has a unique situation and may or may not respond to a specific drug or treatment. The process of finding an effective therapy can be time-consuming, but cancer patients do not have the luxury of time for trial and error. Therefore, a novel organoid technology is presented here, which creates patient-specific organoids (PSO) within one day, utilizing tumor tissues acquired from cancer patients. PSO properties reflect those of its respective original in vivo tumor tissue and can be utilized to perform various in vitro drug sensitivity tests to identify the most effective clinical treatment for patients. Additionally, PSO can aid in assessing the efficacy of immune cell therapies.